| Literature DB >> 31011465 |
Suganya Murugesu1, Zalikha Ibrahim1, Qamar Uddin Ahmed1, Bisha Fathamah Uzir1, Nik Idris Nik Yusoff1, Vikneswari Perumal2, Faridah Abas3, Khozirah Shaari3, Alfi Khatib1,3.
Abstract
The present study used in vitro and in silico techniques, as well as tEntities:
Keywords: Clinacanthus nutans; Diabetes; LC-MS-QTOF; Metabolomics; Molecular docking; α-Glucosidase inhibitors
Year: 2018 PMID: 31011465 PMCID: PMC6460329 DOI: 10.1016/j.jpha.2018.11.001
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
The half maximal inhibitory concentration (IC50) of the α-glucosidase inhibitory activity of the C. nutans leaf fractions.
| Solvent fraction | IC50 (μg/mL, mean ± SD) |
|---|---|
| 3.07 ± 0.05d | |
| 5.54 ± 0.09d | |
| Ethyl acetate (EA) | 8.42 ± 0.17c |
| Ethyl Acetate: Methanol (EM) | 37.45 ± 0.90b |
| Methanol (M) | 133.57 ± 0.30a |
| Quercetin | 5.77 ± 1.01 |
Means that do not share the same letter are significantly different with p value < 0.05.
SD = Standard Deviation. n = 6.
Fig. 1(A) PLS score scatter plot of different solvent fractions from the C. nutans leaves using positive ionization in the LC-MS analysis. H, n-hexane; HE, n-hexane: ethyl acetate; E, ethyl acetate; EM, ethyl acetate: methanol and M, methanol. (B) The loading scatter plot of the PLS model of the fractions analyzed using LC-MS with positive ionization. The identified α-glucosidase inhibitors are: (1) 4,6,8-Megastigmatrien-3-one; (2) N-Isobutyl-2-nonen-6,8-diynamide; (3) 1′,2′-bis(acetyloxy)-3′,4′-didehydro-2′-hydro-β, ψ-carotene; and (4) 22-acetate-3-hydroxy-21-(6-methyl-2,4-octadienoate)-olean-12-en-28-oic acid.
Tentative metabolites identified in the C. nutans leaves fractions through LC-MS/MS fragmentation using positive ionization.
| Compound | M+H | MS2 fragments ions | Tentative metabolites | Refs. |
|---|---|---|---|---|
| 191.2 | [M-CHO]+ at | 4,6,8-Megastigmatrien-3-one | ||
| 204.1 | [M-C2 H5]+ at | N-Isobutyl-2-nonen-6,8-diynamide | ||
| 653.5 | [M-C5 H9 O]+ at | 1′,2′-bis(acetyloxy)-3′,4′-didehydro-2′-hydro-β, ψ-carotene | ||
| 667.5 | [M-C17 H25 O4]+at | 22-acetate-3-hydroxy-21-(6-methyl-2,4-octadienoate)-olean-12-en-28-oic acid |
Fig. 2The bioactive compounds that inhibit α-glucosidase enzyme activity. (1) 4,6,8-Megastigmatrien-3-one; (2) N-Isobutyl-2-nonen-6,8-diynamide; (3) 1′,2′-bis(acetyloxy)-3′,4′-didehydro-2′-hydro-β, ψ-carotene; and (4) 22-acetate-3-hydroxy-21-(6-methyl-2,4-octadienoate)-olean-12-en-28-oic acid.
Fig. 3The LC-MS spectra of all labelled with the mass of the compounds identified. H, n-hexane; HE, n-hexane: ethyl acetate; E, ethyl acetate; EM, ethyl acetate: methanol; and M, methanol.
Molecular interaction results of α-glucosidase enzymatic protein with the known inhibitor (Quercetin) and the active compounds quantified using LC-MS.
| Compound | Binding energy (kcal/mol) | H-bond interacting residues | Other interacting residues |
|---|---|---|---|
| Control ligand | − 6.00 | ASH69, HIE112, GLN182, ARG213, ASH215, GLH277, HIE351, ASP352, ARG442 | TYR72 |
| Quercetin | − 8.15 | LYS156, THR310, PRO312, LEU313, GLU411, ASN415 | PHE314, ARG315 |
| − 7.47 | ASN259, HID295 | TRP15, ALA292, TRP343 | |
| − 5.54 | LYS156 | TYR158, VAL232, VAL313 | |
| − 10.19 | ARG335 | LYS156, TYR158, PRO312, PHE314, ARG315, TYR316 | |
| − 8.31 | GLY209 | VAL232, HIE280, VAL308, PRO312, LEU313, VAL319 |
Fig. 4The 3D diagram showing the superimposed binding site of compounds 1, 2, 3 and 4 with the receptor.